BioMarin Pharma (BMRN) Tops Q4 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- S&P 500, Dow futures muted after big bank earnings, chip slide weighs
- Oil prices ease as traders monitor Russian diesel deal, Saudi attacks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
Tweet
Share
E-mailGet Alerts BMRN Hot Sheet
Price: $55.39 --0%
Revenue Growth %: +31.4%
Financial Fact:
Royalty and license revenues: 1.63M
Today's EPS Names:
PGR, OMID, ACI, More
Revenue Growth %: +31.4%
Financial Fact:
Royalty and license revenues: 1.63M
Today's EPS Names:
PGR, OMID, ACI, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q4 EPS of ($0.47), $0.12 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $230.9 million versus the consensus estimate of $189.01 million.
BioMarin Pharma sees FY2015 revenue of $885-915 million, versus the consensus of $880.6 million.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Johnson & Johnson (JNJ) Tops Q3 EPS by 6c; adjusts forecast
- JPMorgan (JPM) Misses Q3 EPS by 18c, Misses on Revenue
- JD.com (JD) Reiterated at Buy by StoneX Amid Soft Consumption Backdrop
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
